MX2018005490A - Variantes de factor viii reducido en cpg, composiciones, metodos y usos para el tratamiento de trastornos de hemostasia. - Google Patents
Variantes de factor viii reducido en cpg, composiciones, metodos y usos para el tratamiento de trastornos de hemostasia.Info
- Publication number
- MX2018005490A MX2018005490A MX2018005490A MX2018005490A MX2018005490A MX 2018005490 A MX2018005490 A MX 2018005490A MX 2018005490 A MX2018005490 A MX 2018005490A MX 2018005490 A MX2018005490 A MX 2018005490A MX 2018005490 A MX2018005490 A MX 2018005490A
- Authority
- MX
- Mexico
- Prior art keywords
- factor viii
- methods
- cpg reduced
- compositions
- treatment
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 230000023597 hemostasis Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 2
- 102000001690 Factor VIII Human genes 0.000 abstract 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se dan a conocer variantes de ácido nucleico reducido en CpG que codifican la proteína FVIII, y métodos de uso de las mismas. En modalidades particulares, las variantes de ácido nucleico reducido en CpG que codifican FVIII se expresan con mayor eficiencia por las células, se secretan en niveles incrementados por las células por encima de las proteínas Factor VIII de tipo silvestre, exhiben una expresión y/o actividad potenciadas sobre las proteínas Factor VIII de tipo silvestre, o se empaquetan con más eficiencia en vectores virales.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562249001P | 2015-10-30 | 2015-10-30 | |
US201662331872P | 2016-05-04 | 2016-05-04 | |
US201662349532P | 2016-06-13 | 2016-06-13 | |
US201662357874P | 2016-07-01 | 2016-07-01 | |
PCT/US2016/059793 WO2017075619A1 (en) | 2015-10-30 | 2016-10-31 | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005490A true MX2018005490A (es) | 2018-08-16 |
Family
ID=58630834
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005490A MX2018005490A (es) | 2015-10-30 | 2016-10-31 | Variantes de factor viii reducido en cpg, composiciones, metodos y usos para el tratamiento de trastornos de hemostasia. |
MX2023001600A MX2023001600A (es) | 2015-10-30 | 2018-04-30 | Variantes de factor viii reducido en cpg y composiciones para usarse en el tratamiento de trastornos de hemostasia. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001600A MX2023001600A (es) | 2015-10-30 | 2018-04-30 | Variantes de factor viii reducido en cpg y composiciones para usarse en el tratamiento de trastornos de hemostasia. |
Country Status (19)
Country | Link |
---|---|
US (2) | US20180312571A1 (es) |
EP (1) | EP3368560A4 (es) |
JP (2) | JP7088831B2 (es) |
KR (1) | KR20180090795A (es) |
CN (1) | CN108368164A (es) |
AU (1) | AU2016344030B2 (es) |
BR (1) | BR112018008766A2 (es) |
CA (1) | CA3002689A1 (es) |
CL (1) | CL2018001107A1 (es) |
CO (1) | CO2018005306A2 (es) |
IL (1) | IL258959B1 (es) |
MX (2) | MX2018005490A (es) |
MY (1) | MY190926A (es) |
PE (2) | PE20231949A1 (es) |
PH (1) | PH12018501055A1 (es) |
RU (1) | RU2745506C2 (es) |
SA (1) | SA518391463B1 (es) |
SG (1) | SG11201802972UA (es) |
WO (1) | WO2017075619A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
JP6831779B2 (ja) | 2015-06-23 | 2021-02-17 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 修飾された第ix因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用 |
MX2019000962A (es) | 2016-07-26 | 2019-08-01 | Biomarin Pharm Inc | Novedosas proteinas de la capside del virus adenoasociado. |
KR20200066289A (ko) * | 2017-08-01 | 2020-06-09 | 스파크 테라퓨틱스, 인코포레이티드 | 인자 viii (fviii) 유전자 요법 방법 |
TW201920255A (zh) * | 2017-08-09 | 2019-06-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
KR101952102B1 (ko) * | 2017-12-07 | 2019-02-26 | 주식회사 지앤피바이오사이언스 | 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터 |
AU2019265560A1 (en) | 2018-05-09 | 2020-11-26 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
US20200069819A1 (en) | 2018-05-14 | 2020-03-05 | Biomarin Pharmaceutical Inc. | Stable expression of aav vectors in juvenile subjects |
TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
MX2021002198A (es) * | 2018-08-24 | 2021-07-15 | Spark Therapeutics Inc | Secuencias de promotores optimizadas, construcciones de expresion libres de intrones y metodos de uso. |
GB201900702D0 (en) * | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
WO2020168362A1 (en) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Gene editing for hemophilia a with improved factor viii expression |
KR20210151785A (ko) * | 2019-03-13 | 2021-12-14 | 제너레이션 바이오 컴퍼니 | 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도 |
EP4051703A1 (en) * | 2019-11-01 | 2022-09-07 | Freeline Therapeutics Limited | Factor viii polypeptide |
WO2023036054A2 (en) * | 2021-09-08 | 2023-03-16 | Inspirar Limited | Composition and method for treating hemophilia |
WO2023211316A1 (en) * | 2022-04-28 | 2023-11-02 | Joint Stock Company "Biocad" | Codon-optimized nucleic acid encoding the fviii-bdd |
WO2024050039A2 (en) * | 2022-08-31 | 2024-03-07 | Hydrogene Therapeutics, Inc. | Methods and compositions for hydrodynamic gene delivery |
CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
US20060099685A1 (en) | 1999-04-15 | 2006-05-11 | Yallop Christopher A | Recombinant expression of factor VIII in human cells |
US7033994B2 (en) * | 1999-12-24 | 2006-04-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy |
JP2004525608A (ja) * | 2000-09-19 | 2004-08-26 | エモリー ユニバーシテイ | 修飾された因子viii |
DE102004037611B4 (de) * | 2004-08-03 | 2013-10-02 | Geneart Ag | Induzierbare Genexpression |
GB0908515D0 (en) | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
RS58578B1 (sr) | 2011-07-08 | 2019-05-31 | Bioverativ Therapeutics Inc | Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu |
EP3549953A1 (en) * | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
US20140271550A1 (en) | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
CA3209883A1 (en) * | 2013-07-22 | 2015-01-29 | The Children's Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
EP3770169A1 (en) * | 2013-09-12 | 2021-01-27 | BioMarin Pharmaceutical Inc. | Adeno-associated virus factor viii vectors |
WO2015054439A2 (en) * | 2013-10-08 | 2015-04-16 | Haplomics, Inc. | Hybrid factor viii polypeptides for use to treat hemophilia a |
GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
SG11201701033QA (en) * | 2014-08-13 | 2017-03-30 | Philadelphia Children Hospital | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
AU2016343887B2 (en) | 2015-10-28 | 2023-04-06 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
KR20200066289A (ko) | 2017-08-01 | 2020-06-09 | 스파크 테라퓨틱스, 인코포레이티드 | 인자 viii (fviii) 유전자 요법 방법 |
-
2016
- 2016-10-30 PE PE2023001716A patent/PE20231949A1/es unknown
- 2016-10-31 KR KR1020187015213A patent/KR20180090795A/ko not_active Application Discontinuation
- 2016-10-31 CA CA3002689A patent/CA3002689A1/en active Pending
- 2016-10-31 AU AU2016344030A patent/AU2016344030B2/en active Active
- 2016-10-31 MY MYPI2018000612A patent/MY190926A/en unknown
- 2016-10-31 US US15/772,025 patent/US20180312571A1/en active Pending
- 2016-10-31 IL IL258959A patent/IL258959B1/en unknown
- 2016-10-31 PE PE2018000713A patent/PE20181168A1/es unknown
- 2016-10-31 BR BR112018008766A patent/BR112018008766A2/pt active Search and Examination
- 2016-10-31 EP EP16861065.7A patent/EP3368560A4/en active Pending
- 2016-10-31 WO PCT/US2016/059793 patent/WO2017075619A1/en active Application Filing
- 2016-10-31 SG SG11201802972UA patent/SG11201802972UA/en unknown
- 2016-10-31 MX MX2018005490A patent/MX2018005490A/es unknown
- 2016-10-31 JP JP2018521281A patent/JP7088831B2/ja active Active
- 2016-10-31 RU RU2018119710A patent/RU2745506C2/ru active
- 2016-10-31 CN CN201680063183.9A patent/CN108368164A/zh active Pending
-
2017
- 2017-03-17 US US15/462,660 patent/US11168124B2/en active Active
-
2018
- 2018-04-26 CL CL2018001107A patent/CL2018001107A1/es unknown
- 2018-04-29 SA SA518391463A patent/SA518391463B1/ar unknown
- 2018-04-30 MX MX2023001600A patent/MX2023001600A/es unknown
- 2018-04-30 PH PH12018501055A patent/PH12018501055A1/en unknown
- 2018-05-21 CO CONC2018/0005306A patent/CO2018005306A2/es unknown
-
2022
- 2022-06-09 JP JP2022093877A patent/JP2022137029A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022137029A (ja) | 2022-09-21 |
PH12018501055A1 (en) | 2019-01-28 |
US11168124B2 (en) | 2021-11-09 |
CL2018001107A1 (es) | 2018-10-05 |
JP7088831B2 (ja) | 2022-06-21 |
RU2745506C2 (ru) | 2021-03-25 |
AU2016344030A1 (en) | 2018-05-10 |
IL258959A (en) | 2018-06-28 |
US20170216408A1 (en) | 2017-08-03 |
MX2023001600A (es) | 2023-03-09 |
CN108368164A (zh) | 2018-08-03 |
RU2018119710A (ru) | 2019-12-06 |
JP2019503649A (ja) | 2019-02-14 |
EP3368560A4 (en) | 2019-03-27 |
WO2017075619A1 (en) | 2017-05-04 |
CA3002689A1 (en) | 2017-05-04 |
MY190926A (en) | 2022-05-20 |
SG11201802972UA (en) | 2018-05-30 |
US20180312571A1 (en) | 2018-11-01 |
AU2016344030B2 (en) | 2021-05-06 |
BR112018008766A2 (pt) | 2018-10-30 |
RU2018119710A3 (es) | 2020-04-02 |
CO2018005306A2 (es) | 2018-11-30 |
PE20231949A1 (es) | 2023-12-05 |
SA518391463B1 (ar) | 2022-12-13 |
IL258959B1 (en) | 2024-06-01 |
EP3368560A1 (en) | 2018-09-05 |
PE20181168A1 (es) | 2018-07-19 |
KR20180090795A (ko) | 2018-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
SA517380883B1 (ar) | Viii مجموعة تعبير متطورة لحزم والتعبير عن عامل متغير لعلاج اضطراب توقف نزيف الدم | |
MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
CO2018005215A2 (es) | Construcciones específicas del hígado para expresión del factor viii | |
PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2018006840A (es) | Focalizacion de peptidos para dirigir virus adenoasociados. | |
WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
MX2023001119A (es) | Variantes de enzimas y polinucleotidos que las codifican. | |
EA201591992A1 (ru) | Эффективная доставка больших генов посредством двойных aav векторов | |
MX2021015182A (es) | Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso. | |
WO2015109124A3 (en) | Immunomodulatory agents | |
MX2017007731A (es) | Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas. | |
TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
MX2019000140A (es) | Variantes de xilanasa y polinucleotidos que las codifican. | |
MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
WO2016046234A3 (en) | Recombinant phe-free proteins for use in the treatment of phenylketonuria | |
EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
WO2014025771A3 (en) | Methods and compositions for inactivating enveloped viruses | |
MX2022010959A (es) | Terapia genica para trastornos oculares. | |
MY185444A (en) | Enterovirus 71 antiviral peptides |